Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company, has announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, PTSD, and associated disorders. This move signals a potential new avenue for addressing underserved conditions in the central nervous system (CNS) space.
According to the press release, Silo Pharma’s therapeutic focus is on underserved conditions, including stress-induced psychiatric disorders, chronic pain, and CNS diseases. The company’s portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. The ibogaine initiative represents an expansion into novel therapeutics for TBI, a condition with limited treatment options.
The announcement is significant because traumatic brain injury affects millions worldwide, often leading to long-term cognitive and psychological impairments. Current treatments are primarily symptomatic, and there is a critical need for disease-modifying therapies. Ibogaine, a naturally occurring psychoactive compound, has shown promise in preclinical studies for neuroprotection and neuroplasticity, but its use has been limited due to safety concerns. Silo Pharma’s approach may focus on developing safer formulations or delivery systems to harness ibogaine’s therapeutic potential while mitigating risks.
“We are excited to launch this strategic initiative to explore ibogaine-based therapeutics for TBI and related neuropsychiatric conditions,” said a spokesperson for Silo Pharma. The patent filing underscores the company’s commitment to innovation in CNS disorders.
Silo Pharma’s research is conducted in collaboration with leading universities and laboratories. For more information, visit the company’s website at silopharma.com. The full press release is available at https://ibn.fm/HdWHG.
Investors and interested parties can find the latest news and updates at the company’s newsroom: https://ibn.fm/SILO.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative.